SCHEMBL1433994

SCHEMBL1433994

NC(=O)CCCCCCC(=O)Nc1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 19/20 0.74
▸ HDAC4 P56524 18/20 0.74
▸ HDAC1 Q13547 18/20 0.74
▸ HDAC7 Q8WUI4 18/20 0.74
▸ HDAC11 Q96DB2 18/20 0.74
▸ HDAC8 Q9BY41 18/20 0.74
▸ HDAC9 Q9UKV0 18/20 0.74
▸ HDAC5 Q9UQL6 18/20 0.74
▸ HDAC3 O15379 17/20 0.74
▸ HDAC2 Q92769 17/20 0.74
▸ HDAC10 Q969S8 17/20 0.74
▸ NCOR2 Q9Y618 2/20 0.74
▸ NCOR1 O75376 2/20 0.74
▸ KDM4E B2RXH2 1/20 0.74
▸ BRD4 O60885 1/20 0.74
▸ NR1I2 O75469 1/20 0.74
▸ EGFR P00533 1/20 0.74
▸ CYP3A4 P08684 1/20 0.74
▸ LTA4H P09960 1/20 0.74
▸ NR0B1 P51843 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1065527 1.00 HDAC6 (0.74) HDAC6HDAC4HDAC1HDAC7HDAC11
SCHEMBL10497217 0.98 HDAC6 (0.71) HDAC6HDAC4HDAC1HDAC7HDAC11
SCHEMBL608911 0.94 HDAC4 (0.66) HDAC6HDAC4HDAC1HDAC7HDAC11
Hydroxyamine SCHEMBL1268824 0.92 HDAC6 (0.79) HDAC6HDAC4HDAC1HDAC7HDAC11
SCHEMBL6669511 0.92 HDAC4 (0.85) HDAC6HDAC4HDAC1HDAC7HDAC11
SCHEMBL137348 0.92 HDAC4 (0.85) HDAC6HDAC4HDAC1HDAC7HDAC11
SCHEMBL6665592 0.92 HDAC4 (0.85) HDAC6HDAC4HDAC1HDAC7HDAC11
SCHEMBL1065393 0.92 HDAC4 (0.85) HDAC6HDAC4HDAC1HDAC7HDAC11
SCHEMBL29266758 0.92 SOAT2 (0.74) HDAC6HDAC4HDAC1HDAC7HDAC11
SCHEMBL517309 0.90 HDAC4 (0.81) HDAC6HDAC4HDAC1HDAC7HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109651199-B Histone deacetylase and microtubule double-target inhibitor and preparation method thereof 青岛大学 2022-01-04 — — CN claimed
EP-3407913-A1 USE OF HISTONE DEACETYLASE INHIBITORS FOR ENHANCING IMMUNOTHERAPIES Indiana University Research & Technology Corporation (US) 2018-12-05 — — EP claimed
WO-2018160676-A1 COMPOSITIONS AND METHODS FOR REACTIVATING LATENT HIV-1 INFECTIONS UNIVERSITY OF THE SCIENCES (US) 2018-09-07 — — WO claimed
WO-2017132536-A1 USE OF HISTONE DEACETYLASE INHIBITORS FOR ENHANCING IMMUNOTHERAPIES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2017-08-03 — — WO claimed
US-9693994-B2 Class IIa HDAC inhibitors for the treatment of infection RESEARCH DEVELOPMENT FOUNDATION (US) 2017-07-04 — — US claimed
WO-2015157500-A1 CLASS IIA HDAC INHIBITORS FOR THE TREATMENT OF INFECTION RESEARCH DEVELOPMENT FOUNDATION (US) 2015-10-15 — — WO claimed
WO-2013022715-A2 PBAP48 TRANSGENIC MICE FOR DRUG DISCOVERY IN AGE-RELATED MEMORY DECLINE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2013-02-14 — — WO claimed
EP-2544673-A1 THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER Spectrum Pharmaceuticals, Inc. (US) 2013-01-16 — — EP claimed
WO-2012162535-A1 USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION LIXTE BIOTECHNOLOGY, INC. (US) 2012-11-29 — — WO claimed
WO-2011112623-A1 THIOXANTHONE-BASED AUTOPHAGY INHIBITOR THERAPIES TO TREAT CANCER SPECTRUM PHARMACEUTICALS, INC. (US) 2011-09-15 — — WO claimed
WO-2011061545-A1 HPLC METHOD FOR ANALYZING VORINOSTAT GENERICS [UK] LIMITED (GB) 2011-05-26 — — WO claimed
WO-2010028193-A1 COMPOUNDS INCLUDING PIMELIC ACID DERIVATIVES AS HDAC INHIBITORS REPLIGEN CORPORATION (US) 2010-03-11 — — WO claimed
WO-2024263963-A2 COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING HEAD AND NECK CANCER BURZYNSKI STANISLAW R (US) 2024-12-26 — — WO disclosed
WO-2024263972-A2 COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING UNCOMMON CANCERS BURZYNSKI STANISLAW R (US) 2024-12-26 — — WO disclosed
WO-2024263804-A2 COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING KIDNEY CANCER BURZYNSKI STANISLAW R (US) 2024-12-26 — — WO disclosed
WO-2024263798-A1 COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PROSTATE CANCER BURZYNSKI STANISLAW R (US) 2024-12-26 — — WO disclosed
US-20070100559-A1 Crystal structure of a deacetylase and inhibitors thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2007-05-03 — — US disclosed
US-20070100559-A1 Crystal structure of a deacetylase and inhibitors thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2007-05-03 — — US disclosed
US-20070087427-A1 Crystal structure of a deacetylase and inhibitors thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2007-04-19 — — US disclosed
US-20070087427-A1 Crystal structure of a deacetylase and inhibitors thereof SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2007-04-19 — — US disclosed
Send feedback